The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | P | Antiparasitic products, insecticides and repellents | |
| 2 | P02 | Anthelmintics | |
| 3 | P02C | Antinematodal agents | |
| 4 | P02CA | Benzimidazole derivatives |
| Code | Title | |
|---|---|---|
| P02CA01 | Mebendazole | |
| P02CA02 | Tiabendazole | |
| P02CA03 | Albendazole | |
| P02CA04 | Ciclobendazole | |
| P02CA05 | Flubendazole | |
| P02CA06 | Fenbendazole | |
| P02CA51 | Mebendazole, combinations |
| Active Ingredient | Description | |
|---|---|---|
| Albendazole |
Albendazole causes degenerative alterations in the tegument and intestinal cells of the worm by binding to the colchicine-sensitive site of tubulin, thus inhibiting its polymerization or assembly into microtubules. |
|
| Flubendazole |
|
|
| Mebendazole |
In vitro and in vivo work suggests that mebendazole blocks the uptake of glucose by adult and larval forms of helminths, in a selective and irreversible manner. Inhibition of glucose uptake appears to lead to endogenous depletion of glycogen stores within the helminth. Lack of glycogen leads to decreased formation of ATP and ultrastructural changes in the cells. |
|
| Tiabendazole |
|
| Title | Information Source | Document Type | |
|---|---|---|---|
| ALBENZA Film-coated tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| VERMOX Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
